By Adriano Marchese
Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter.
Shares were trading 14% lower at $19.11.
The biopharmaceutical oncology company reported a loss of $61.2 million, or 8 cents a share, compared with a loss of $36.6 million, or 5 cents a share a year earlier.
Expenses also rose. Adjusted operating expenses came to $54.8 million from $27.7 million.
Additionally, Summit Therapeutics plans to work with Pfizer to study its promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates in solid tumors.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 24, 2025 10:19 ET (15:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。